CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors.
Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
经工程改造表达嵌合抗原受体(CAR)的T细胞治疗血液系统恶性肿瘤已显示出很高的缓解率。然而,实体瘤存在多重挑战,限制CAR-T 细胞的抗肿瘤疗效,包括抗原异质性、肿瘤外及全身毒性,以及免疫抑制性肿瘤微环境(TME)。值得注意的是,实体瘤TME存在趋化因子失调,结构致密,由肿瘤基质、细胞外基质和异常血管构成,阻碍CAR-T 细胞迁移至肿瘤部位并浸润实体瘤组织。本综述重点介绍促进CAR-T 细胞向实体瘤迁移和浸润的近期进展,以增强CAR-T 细胞对抗原的有效识别。
T cells engineered to express chimeric antigen receptors (CARs) have demonstrated robust response rates in treating hematological malignancies.
However, solid tumors present multiple challenges that hinder the antitumor efficacy of CAR-T cells, including antigen heterogeneity, off-tumor and systemic toxicities, and the immunosuppressive milieu of the tumor microenvironment (TME).
Notably, the TME of solid tumors is characterized by chemokine dysregulation and a dense architecture consisting of tumor stroma, extracellular matrix, and aberrant vasculature that impede migration of CAR-T cells to the tumor site as well as infiltration into the solid-tumor mass. In this review, we highlight recent advances to improve CAR-T-cell trafficking to and infiltration of solid tumors to promote effective antigen recognition by CAR-T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。